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• Progress in glioblastoma (GBM) management and monitoring has been disappointing, 
with the single major advancement resulting in an improved median survival of only 14 
months and 26% 2-year survival with death inevitably being due to recurrence that is 
often local. 
• Gold standard for GBM diagnosis is via biopsy or open resection, two invasive 
approaches with the latter having a minor association with morbidity; both subject to 
sampling error as a result of intratumoral heterogeneity. 
• Current treatment involves maximum resection, via white light or fluorescence with 5-
aminolevulinic acid, followed by radiotherapy (RT) with concomitant and adjuvant 
temozolomide (TMZ), with complete resections (less than 2% of contrast enhancement 
remaining) being associated with improved progression-free survival. 
• Underlying intrinsic and extrinsic biological features, including a heterogeneous tumor 
microenvironment, result in RT and TMZ having limited and varied effect, especially with 
cancer cells migrating through the tumor margin, which includes healthy and normal-
appearing brain. 
• Cancer cells surviving treatment may evolve with conferred resistance to adjuvant TMZ. 
• Post-treatment monitoring of GBM relies on visual and manual analysis of conventional 
T1-weighted contrast enhancement and T2-weighted fluid attenuated inversion recovery 
images, which demonstrate limited and non-specific features of blood brain barrier 
permeability and tissue water content, respectively. 
• These conventional imaging methods are unable to specifically identify treatment-induced 
changes in a timely manner, limiting the ability to distinguish pseudoprogression from true 
tumor progression. 
• Emerging imaging techniques that rely on specific underlying biological tumor properties 
lack validation and standardization, rendering them non-useful for current clinical 
assessment of GBM. 
• Appropriate endpoints and methodologies for these emerging imaging methods need to 
be determined before they can be reliably included in clinical trials for GBM.  
• Advanced imaging studies, focusing on the non-enhancing invasive margin, are needed 
for assessing regional tumor response to treatment for further understanding of GBM 
invasion and recurrence, and improvement of patient management. 
 
SUMMARY  
Glioblastoma demonstrates imaging features of intratumor heterogeneity that result from 
underlying heterogeneous biological properties.  This stems from variations in cellular 
behavior that result from genetic mutations that either drive, or are driven by, heterogeneous 
microenvironment conditions.  Amongst all imaging methods available, only T1-weighted 
contrast-enhancing and T2-weighted fluid attenuated inversion recovery are used in standard 
clinical GBM assessment and monitoring. Advanced imaging modalities are still considered 
emerging techniques as appropriate endpoints and robust methodologies are missing from 
clinical trials.  Discovering how these images specifically relate to the underlying tumor 
biology may aid in improving quality of clinical trials and understanding the factors involved 
in regional responses to treatment, including variable drug uptake and effect of radiotherapy. 
Upon validation and standardization of emerging MR techniques, providing information 
based on the underlying tumor biology, these images may allow for clinical decision-making 
that is tailored to an individual’s response to treatment.  
Keywords: glioblastoma; intratumor heterogeneity; advanced imaging; underlying biology; 
sub-regional assessment   
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults.  
Even under optimal treatment conditions, median survival is only 14 months with a 26% 2-
year survival rate [1] and patient death results from inevitable tumor progression. 
Recurrence is often local and not easily detected using conventional magnetic resonance 
imaging (MRI).  Amongst all options available for treatment, extent of resection is the only 
variable that neurosurgeons can affect [2].  In spite of the incorporation of 5-Aminolevulinic 
acid (5-ALA) improving maximal resection and 6-month progression free survival (PFS) [3], 
poor drug delivery and relative radiotherapy (RT) resistance [4] contribute to poor prognosis.  
Though the progress in GBM management has been disappointing, with the single major 
advancement in the past decades being the incorporation of RT with concomitant and 
adjuvant temozolomide (TMZ) [1], there has been exponential growth in the advancements 
of MRI techniques for non-invasive characterization of GBM. In parallel, advancements in 
genomic tool development for molecular analysis on a genome-wide level have also been 
ongoing [5].  With this, work has begun for merging imaging information with that of the 
underlying biology driving intratumor heterogeneity of GBM.  
 
Intratumor heterogeneity of glioblastoma: what is it and why does it occur? 
Tumor heterogeneity refers to biological differences between malignant cells in a same 
cancer, where variations in genetic alterations and phenotypic inconsistencies (including 
cellular metabolism, resilience and behavior) can drive tumor cell diversity within an 
individual tumor (intratumor heterogeneity) or among patients with the same tumor 
(intertumor heterogeneity) [6].  
During tumor development, malignant cells evolve together with the extra-cellular matrix, 
microvasculature, stromal and immune cells [7]. Regional variations that arise from this 
coevolution are presumed to be a partnership of distinct ecosystems of cells, for which the 
microenvironment would be, in the primary instance, influenced by inconsistencies in 
vasculature and blood supply. The resulting microenvironment conditions would include 
subsequent regional inflammation, hypoxia and acidosis with limited glucose supply. This 
would set the scene for selective pressures, giving rise to regional cellular adaptations – a 
Darwinian concept of adaptive response.  Heterogeneity, therefore, can arise through 
extrinsic mechanisms that confer functional differences to the malignant cells [8].  In a recent 
study, GBM cells isolated from two different microenvironments, the tumor core and margin, 
each demonstrated different phenotype and stem-cell signature whilst propagated within the 
same culture conditions [9].  Tumor cell diversity can also arise through genomic instability 
and differential response of clones to therapy, where cellular proliferation does not result in 
clusters of identical cells. Instead, many sub-clones are developed through complex spatial 
and temporal evolutionary trajectories [6,10,11].   
 
What is the implication of intratumor heterogeneity on management of glioblastoma?  
Intratumor heterogeneity is a dynamic state, which is most likely the primary force driving 
differential responses to therapy, development of treatment resistance and, ultimately, tumor 
recurrence [8,10–12].  RT and TMZ create a selective evolutionary pressure on GBM cells to 
which they are exposed. Microenvironment conditions that prevent treatment from having 
effect may result in surviving cells that proliferate to form clusters of cancer cells with 
conferred resistance, meaning that a single drug may not be enough for efficient treatment. 
Combined therapies appear to be the way forward; these would need to target trunk 
alterations of clonally dominant tumor drivers [13]. Problematically, passenger mutations can 
become drivers in response to environmental pressures caused by treatment [14]. 
Therapy of GBM requires, in addition to target tumor cells being in cycle, tissue oxygenation. 
This, in turn, requires adequate blood supply. Though angiogenesis is a feature of GBM, the 
new circulation systems are usually tortuous, leaky and chaotic, creating an environment of 
inconsistent blood supply with resultant regional hypoxia and interstitial hypertension [15,16], 
in spite of increased angiogenesis. Hypoxia reduces the effects of radiation-induced DNA 
damage of GBM cells (the oxygen-fixation hypothesis) [17] and recurrence often occurs 
within a few centimeters of the primary lesion [18].  Additionally, the go or grow hypothesis 
[19], states that the migrating phenotype is different to that of the proliferative one, where 
invading cells are not proliferative and, therefore, not affected by RT.  The heterogeneously 
leaky microvasculature also results in increased interstitial fluid pressures (IFP) and non-
uniform drug delivery [16,20], with intrinsic cellular properties also playing a role [21]. 
Furthermore, secondary somatic mutations emerge as result of therapies, contributing to 
changes in the tumor clonal architecture [13] and activation of genes of drug resistance. 
 
Conventional imaging for monitoring intratumor heterogeneity of glioblastoma:  why 
is it not enough? 
Currently, conventional imaging (Table 1), including T1-weighted and T2-weighted fluid 
attenuated inversion recovery (FLAIR), are used for surgical planning and monitoring of 
GBM.  These conventional sequences, though widely available, are limited with their 
representation of regional biological features driving tumor pathology (Figure 1).   T2-
weighted FLAIR has been, since 2006, included in tumor characterization to identify regions 
of surrounding edema of GBM [22]. It does not, however, differentiate between pure 
vasogenic and infiltrative edema, which is a GBM feature.   
Increased or new T1-weighted contrast enhancement does not necessarily imply tumor 
recurrence.  The damage to epithelial cells along with local tissue inflammation caused by 
cytotoxic or radiation therapy are hypothesized to result in the increased edema on T2-
weighted and increased or even new contrast enhancement on T1-weighted images [23], 
mimicking tumor progression.  Though pseudoprogression was described in the late 1980s 
[24], its detailed mechanisms driving tissue damage, along with the inflammatory responses, 
are still not well understood. Conversely, pseudoresponse, which involves the decrease in 
T1-weighted contrast enhancement following treatment, is likely the result of normalization of 
abnormally permeable and leaky tumor vasculature, mimicking tumor response to therapy.  
The Response Assessment in Neuro-Oncology (RANO) criteria suggest that these features 
should persist at least 4 weeks before true response can be considered [25], further 
rationalizing the use of complementary imaging modalities for more prompt characterization 
of post-treatment tumor behavior. 
 
Advanced imaging for monitoring intratumor heterogeneity of glioblastoma: Can one 
see the biology? 
Advanced imaging methods (Table 2) allow for the assessment of GBM based on regional 
biological properties found within and surrounding the tumor.  These include, but are not 
limited to, diffusion-weighted (DWI), diffusion tensor (DTI), diffusional kurtosis (DKI), 
perfusion-weighted (PWI), MR spectroscopic (1H-MRS) and positron emission tomographic 
(PET) imaging.  Though explored by various groups for some years, these emerging 
techniques require further investigation, validation and standardization.  
 
Diffusion imaging 
Diffusion imaging essentially provides information pertaining to the nature of water molecule 
movement within biological tissue.  As the biology of the edematous invasive margin is 
different to that of the tumor bulk [9], the development of imaging techniques for GBM 
characterization, that also focus on the margin as a region of interest, is paramount for the 
incorporation of advanced imaging in assessment criteria of GBM.  
DTI is a modification of DWI that is sensitive to the anisotropic diffusion of water along 
axonal fibers, where one can decompose the diffusion tensor into isotropic (p-) and 
anisotropic (q-) components. By assessing the disruption of white matter (identified as a 
decrease in q) with adjacent edema (identified as an increase in p), DTI has allowed for 
differentiation of the tumor bulk from the invasive margin [26,27], which can extend beyond 
the T2-weighted FLAIR abnormality (Figure 2). The underlying biology observed with DTI 
beyond that of white matter integrity is not well described, making it a technique that is 
limited in providing detailed information of the microenvironment.  DTI has, however, been 
used to identify patterns of recurrence [28] and white matter invasion in GBM [29], with 
improved delineation of the invasive margin [30]. Interestingly DTI-derived characteristics of 
white matter invasion have also been associated with isocitrate dehydrogenase 1 (IDH-1) 
status, where IDH-1-positive tumors, associated with improved prognosis, have 
demonstrated patterns of minimal invasion surrounded by intact white matter [31].   
The apparent diffusion coefficient (ADC) measures motional processes, like flow and 
diffusion. However, when assessing mean ADC values of entire lesions, results can be 
ambiguous as different treatment strategies provide different microenvironments. 
Inconsistencies in study results can be attributed to biological intratumor heterogeneity, 
where an entire lesion is composed of various sub-regions, each possessing characteristic 
quantitative values, recapitulating cellular and molecular phenomena. The entire lesion, 
however, is quantitatively represented as an average of values from all sub-regions with both 
a skewed and large distribution (Figure 3).  
Without taking into account what other imaging modalities could contribute to the picture, 
increased and decreased ADC values, as in vitro studies show [32], may represent different 
events within different treatment settings.  In pre-treatment scans (Figure 3), regions of low 
ADC may be representative of 1) densely packed tumor cells that restrict extracellular water 
movement, or 2) regional ischemia resulting in faulty cellular ion efflux; high ADC could 
represent 1) vasogenic edema, resulting from a disrupted blood-brain barrier (BBB), 2) 
regions with less tumor cells, allowing extracellular water to move freely; or 3) necrotic 
tissue. Post-cytotoxic treatment scans may show regionally decreased ADC resulting from 1) 
cytotoxic edema, during which cells swell due to ion imbalances caused by cell wall damage, 
or 2) recurrent tumor.  Increased ADC after cytotoxic therapy, also an early sign of possible 
pseudoprogression [33], can indicate either 1) cell death or necrosis, where one finds 
increased water motility in extracellular spaces, or 2) an inflammatory response with 
subsequent peritumoral edema. With inflammation, however, comes an inflammatory cell 
response, which may contribute to possible decreases in regional ADC, further warranting 
caution when using ADC to assess and monitor GBM.  In an anti-angiogenic therapy-setting, 
histogram studies vary. One has found low ADC to correlate with better survival patterns 
[34]. A subsequent analysis associated high ADC with increased levels of extracellular 
matrix protein gene expression [35], believed to enhance tumor invasion by promoting 
collagen-enriched matrices for rapid migration [36]. Other studies have, conversely, found an 
association of low ADC with poor outcome [37] in recurrent GBM. The latter comes from a 
multicenter study and is in agreement with more specific histological analyses of regional 
ADC demonstrating an inverse correlation between tumor cell density and ADC [38]. Low 
ADC has also been suggested for use during image-guided biopsies of tumor-containing  
regions in areas of FLAIR abnormality [39]. 
Changes in regional ADC are apparent before changes in conventional imaging features 
[40]. Functional diffusion maps (fDM), which take the intratumoral heterogeneity of ADC into 
account, produce regional color maps according to whether ADC-values have increased, 
decreased or remained unchanged. Studies have used fDMs to predict responses to therapy 
as early as three weeks from start of chemo-RT [41,42].    
Diffusional measurements, though widely explored, still offer a range of metrics that have not 
yet been fully explored. For example, DKI [43], a spin-off from DTI and histogram analysis, is 
a statistic that quantifies non-Gaussian properties of lesions, where a value of kurtosis 
serves as a marker of diffusional heterogeneity. Though explored as a measure of 
heterogeneity during grading [44], DKI has not yet been applied to assessing sub-regional 
heterogeneity in GBM. Though diffusion imaging has shown promise in various aspects of 
assessment, GBMs are spatially heterogeneous tumors, where regions of high cellularity can 
be found adjacent to areas of necrosis and edema, highlighting the importance of a 
multimodal imaging approach for improved regional GBM characterization. 
 
Perfusion imaging 
PWI dynamic susceptibility contrast imaging (DSCI) measures of relative cerebral blood 
volume (rCBV) correlate with regional tumor vascularity [45,46] and cellular proliferation [47].  
As with diffusion, perfusion can vary significantly with changes in cell density, edema and 
necrosis, and various biological situations can be presumed during regional assessment 
[48].  Within the ‘necrotic core’ of contrast-enhanced images (Figure 4), regional low rCBV 
would presumably represent a cell population that was unable to adapt to a hypoxic and/or 
acidic environment. A poorly perfused, yet cellular, region may be indicative of an adaptive 
cell niche (Figure 4). This niche is of importance as it implies the evolution of a cell 
population resistant to regular causes of necrosis or apoptosis- these may be resistant to 
current chemo-RT. Dynamic contrast enhancement (DCE) MRI relies on compartment-
based tracer kinetic models, where certain parameters can be used to describe BBB integrity 
and leakiness of blood vessels [49,50].  These parameters can be used to indirectly describe 
biological properties, including relative IFP.  However, most work, with the exception of one 
[50], has focused primarily on summary statistics, such as the median or mean, of DCE 
parameters without taking into account the regional heterogeneity of GBM. As with ADC, 
extreme values within PWI niches result in mean values that do not necessarily represent 
what is happening within the entire lesion. As mentioned, resistance to drug delivery is 
caused, at least in part, by impaired microvasculature and lymphatic system function, 
leading to increased IFP [16], making DCE another potential PWI method for characterizing 
GBM based on regional IFPs, which may be responsible for regional inadequate drug uptake 
in both the tumor bulk and the non-enhancing invasive margin.  
Following chemo-RT, increased perfusion measures can occur prior to changes in T1 
contrast-enhancement [51]. PWI measures have been utilized for differentiating 
pseudoprogression from true recurrence [52,53] and studies have found certain parameters, 
including rCBV [47,51], to change in the non-enhancing margin of GBM [54]. This makes 
standardized PWI [49,55] a potential tool for future analyses of, not only the enhancing 
tumor bulk, but also the non-enhancing component that is left behind post-surgery.  
 
Spectroscopic imaging 
Multivoxel MRS, or chemical shift imaging (CSI), reveals changes in tissue metabolism.  
Metabolic data have been used not only independently, but also as complementary 
techniques to improve tumor characterization in combination with parameters of DWI [56,57] 
and PWI [58,59].  CSI also provides additional information for better understanding of the 
microenvironment, such as increased cellular density, identified as an increase in levels of 
Choline (Cho) [56]; neuronal damage, identified as a decrease in N-acetylaspartate (NAA) 
levels; and tumor metabolism with associated hypoxia and acidosis, identified as increased 
lactate and lipid production [60].  Studies looking at margin delineation [61] and 
characterization using CSI have reported increased Cho/NAA ratio in the non-enhancing 
component of GBM [62–64], where an increase of this ratio coincides with an increase in 
degree of invasion [65].  Conversely, studies have correlated Cho/NAA ratio with tumor cell 
proliferation [61,66]. This conflict in findings, where the similar results are reported to 
correlate with proliferation and invasion, two cellular processes reported to carry different 
phenotypic characteristics in GBM, highlights the need for caution when relying on MRS CSI 
for regional characterization of these tumors.  Nonetheless, this imaging approach 
demonstrates potential, especially when combining this modality with other advanced 
imaging methods.   
 
Positron emission tomography 
Using a tracer to functionally image tumor metabolic activity, PET has been used in studies 
of GBM treatment effects. 18F-flurodeoxyglucose (FDG) PET, which, until recently, has been 
the most widely used, allows one to image regional glucose metabolism, but is of limited 
value as normal brain naturally demonstrates high glucose uptake. Though amino acid (AA) 
PET, including C-methionine (MET) and 18F-fluoroethyltyrosine (FET), have shown potential 
in assessing effects of RT [67], including identification of true progression [68], it appears to 
be less effective than DWI under direct comparison [69].    3’-Deoxy-3’-18F-fluorothymidine 
(FLT), in addition to MET, is a useful biomarker of cellular proliferation in GBM, with the 
regional heterogeneity of uptake correlating to with MIB-1 labelling index [70]. This, in turn, 
correlates with FLT transport across the BBB [71].  Though contrast with FLT is better than 
with FDG [72], uptake is BBB-determined, which poses a problem in GBM analysis, whose 
BBB is characteristically leaky around contrast-enhancing components. Effects of RT have 
been examined using FLT. These findings, however, have largely involved animal studies 
[73]. To assess potential malignancy based on cellular membrane metabolism, 18F-
fluorocholine (CHO PET) has gathered attention in GBM monitoring, with increased CHO 
uptake being characteristic of high-grade gliomas [74]. To assess response to 
antiangiogenic therapies, 18F-fluciclatide, has been used to visualize regional integrin, which 
plays a key role in angiogenesis [75]. Furthermore, hypoxia markers, such as 18F-
fluoromisonidazole (FMISO), continue to be investigated for predicting response to RT [76] 
and bevacizumab.  As drug delivery in tumors is heterogeneous [20], PET tracers for specific 
drugs with positron emitters would produce images of tracer uptake that are representative 
of regional drug uptake, making PET an imaging tool of significant potential. 
 Conclusion & Future Perspective 
The complex dynamics of biological systems in GBM result in heterogeneous and 
inconsistent imaging features.  It is becoming evident, however, that regional variations 
within GBM result in specific imaging characteristics. Very little is known of the molecular 
and genomic properties found within separate niches in GBM, but having an idea of the 
microenvironment they inhabit, could provide details of the adaptive strategies undertaken 
for cell survival. Therefore, a valuable metric for future GBM analysis could involve 
assessment of MRI-defined ‘habitat’ changes in response to therapy. This would be 
beneficial in personalized treatment, such as the implementation of boost RT dosing in 
regions of high risk.    
Though the potential appears promising, the use advanced imaging as surrogate measures 
of tumor biology carry limitations. In addition to inter-observer variability, limitations include 
enhancing variability, measurement variability, as well as false positives and negatives [77].  
This highlights the need for future refinement in the assessment criteria with a particular 
focus on standardization [49,55] of imaging characteristics along with clearer understanding 
of underlying biological properties, whether they are at the cellular, molecular or genetic 
level. This would potentially minimize errors caused by intrinsic parametric variation, and 
enhance the accuracy of assessing response to treatment [22] in a multicenter setting. 
Determining the added value of assessing non-enhancing tumor progression, as a measure 
of clinically relevant and treatment-related change, and incorporating into the assessment 
criteria, may too be a way forward. This will most likely be achieved with identification of 
appropriate endpoints in multicenter trials. Additionally, a shift to three-dimensional 
assessment [25] will improve the understanding of regional spatial dynamics. Furthermore, 
assessing regional volumes, as opposed to areas, would preserve statistical power of results 
whilst using a smaller patient cohort. 
As future directions for GBM management probably involve multimodal therapy directed at 
multiple sub-regions, the advantages obtained with a detailed understanding of regional 
imaging properties, and the underlying eco-biology, will contribute to improved strategies for 
personalized medicine of GBM. 
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Table 1. Conventional MR imaging modalities for assessment of glioblastoma. 
Modality Biological properties visualized Limitations 
Conventional 
T1-weighted 
Anatomy; BBB permeability/ 
disruption; compromised vessel 
integrity 
Lacks biological specificity; does not clearly identify tumor 
‘bulk’ boundaries; the ‘necrotic core’ component may not 
exclusively possess necrotic tissue as implied. 
Conventional 
T2-weighted 
Anatomy; tissue water content/ 
edema 
Lacks biological specificity; limited identification of 
invasive/non-invasive tissue; does not accurately 




visualization of edema with less 
‘noise’ from the ventricles. 
Does not show full extent of margin; does not accurately 
differentiate pure vasogenic from infiltrative edema. 
















Table 2. Emerging MR imaging modalities for assessing intratumor heterogeneity in glioblastoma. 
Modality Biological properties visualized †Limitations 
DWI Signal drop in regions of free-moving (Gaussian) 
diffusion. 
Should not be assessed without corresponding T2-
weighted or proton density image as the T2-signal can 
affect DWI signal (T2-shinethrough); non-quantifiable. 
ADC Quantifiable; High signal may indicate: cystic 
lesions, edema, low cellularity, necrosis;  
Low signal may indicate: cytotoxic edema, 
cellularity. 
Cannot differentiate tumor cells from inflammatory 
cells. 
DTI White matter integrity based on infiltration, 
displacement or disruption; with this, one can 
distinguish tumor bulk from the surrounding 
margin.  
Provides details solely pertaining to isotropic and 




BBB disruption, 'leaky' vasculature Model-dependent: based on either flow-limited or 
permeability-limited conditions. Model details can be 
found in work by Tofts and colleagues [49]. 
T2*-weighted 
DSCI 
Regional ††rCBV Due to BBB disruption, T2*signal drops with 
recirculation of blood. As the rCBV model assumes an 
intact BBB, leakage correction is essential to account 
for damaged and leaky BBB in GBM. 
1H-MRS CSI Metabolic changes; microenvironment: high Cho = 
membrane turnover (cellularity); low NAA = 
damaged neurons; lactate & lipids = anaerobic, 
acidic conditions 
Improved spectra resolution comes at the cost of 
increased acquisition time (longer time in the scanner); 
scanning time further increases when obtaining 3-D 
data. 
†A limitation relevant to these imaging modalities, the emerging ones in particular, is a lack of validation and standardization; 
††Though various metrics can be derived using T2*-weighted imaging, only rCBV is focused on as it is the one most analyzed, 
showing greatest promise in terms of potential standardization [55]. 
DWI: diffusion-weighted imaging; ADC: apparent diffusion coefficient; DTI: diffusion tensor imaging; DCE: dynamic contrast 
enhanced; BBB: Blood-brain barrier; DSCI: Dynamic susceptibility contrast imaging; rCBV: relative cerebral blood volume; GBM: 
Glioblastoma; 1H-MRS CSI: Magnetic resonance spectroscopy chemical shift imaging; Cho: Choline; NAA: N-acetylaspartate 3-
D: Three-dimensional.  
 
 
 
 
